Pacific Biosciences of California (NASDAQ:PACB) Stock Keeps Neutral Rating at Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Pacific Biosciences of California (NASDAQ:PACB) in a report issued on Thursday,Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock, up from their prior target price of $2.00.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. Wall Street Zen downgraded Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, UBS Group assumed coverage on shares of Pacific Biosciences of California in a research report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price target for the company. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Pacific Biosciences of California presently has an average rating of “Reduce” and a consensus price target of $2.09.

Pacific Biosciences of California Trading Down 4.7%

NASDAQ:PACB opened at $2.43 on Thursday. The company has a market cap of $755.32 million, a P/E ratio of -5.79 and a beta of 2.21. Pacific Biosciences of California has a twelve month low of $1.07 and a twelve month high of $3.43. The company’s 50-day moving average price is $1.91 and its 200-day moving average price is $1.62.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $40.56 million for the quarter, compared to analyst estimates of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. On average, analysts expect that Pacific Biosciences of California will post -0.52 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mark Van Oene sold 26,911 shares of Pacific Biosciences of California stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total value of $30,409.43. Following the completion of the transaction, the insider owned 2,705,853 shares in the company, valued at $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James R. Gibson II sold 661,815 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total transaction of $2,058,244.65. Following the completion of the sale, the insider directly owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. This represents a 37.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pacific Biosciences of California

Several institutional investors have recently added to or reduced their stakes in the business. Essential Partners LLC acquired a new stake in Pacific Biosciences of California during the 1st quarter worth $25,000. Choreo LLC purchased a new stake in Pacific Biosciences of California during the 3rd quarter valued at approximately $27,000. Interchange Capital Partners LLC acquired a new stake in Pacific Biosciences of California during the 3rd quarter worth approximately $28,000. Corient Private Wealth LP acquired a new stake in Pacific Biosciences of California during the 2nd quarter worth approximately $30,000. Finally, Pinegrove Venture Partners LLC acquired a new position in shares of Pacific Biosciences of California in the second quarter valued at approximately $34,584.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported a Q3 loss of $0.11 per share, narrower than analysts’ expected $0.13 loss. Revenue of $40.56 million also topped the $39.31 million consensus estimate. PacBio Q3 2026 results
• Positive Sentiment: Piper Sandler raised its price target to $3 from $2 while maintaining a Neutral rating, signaling greater potential upside in its view. Piper Sandler rating
• Neutral Sentiment: The company narrowed its 2026 revenue outlook to $155 million–$160 million and continues to target cash-flow breakeven in 2028. The tighter range may offer more clarity, while the breakeven timeline highlights that profitability remains years away. Revenue guidance and breakeven target
• Neutral Sentiment: PacBio announced CFO changes; the available report headline does not provide details on the transition or its expected impact. CFO changes announcement
• Negative Sentiment: Barclays raised its target to $2 from $1.25 but retained an Underweight rating, indicating it still sees downside from the referenced share price. That cautious stance contrasts with Piper Sandler’s higher target. Barclays rating

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.